1768-1769 / 2605
S
T
R
A
T
I
F
Y
Stage
•
II
•
IIIA
•IIIB
Histology
•
Squamous
•Non-Squamous
Concurrent Chemotherapy
Doublet Type
•
Carbopla4n/paclitaxel
•
Cispla4n/etoposide
R
A
N
D
O
M
I
Z
E
Arm 1
: Photon dose—70 Gy*, at 2 Gy (RBE) once
daily plus pla4num-based doublet chemotherapy
Arm 2
: Proton dose—70 Gy (RBE), at 2 Gy once daily
plus pla4num-based doublet chemotherapy**
Both Arms
:
Consolida4on
chemotherapy x 2
cycles required for
pa4ents who receive
concurrent
carbopla4n and
paclitaxel***
RADIATION THERAPY ONCOLOGY GROUP (RTOG 1308)
PHASE III RANDOMIZED TRIAL COMPARING OVERALL SURVIVAL AFTER PHOTON
VERSUS PROTON CHEMORADIOTHERAPY FOR INOPERABLE STAGE II-IIIB NSCLC
Required Sample Size
: 560 patients
*The total prescribed dose will be 70 Gy [Relative Biological Effectiveness (RBE)]
without
exceeding tolerance dose-volume limits of all critical normal structures
.
NRG (RTOG) – Phase III protocol – open for accrual